We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWhen making a decision about the approval of a new product NICE (National Institute for Health and C...
Read moreInnovative therapies for rare diseases may only be available in a select number of countries in Euro...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNHS England, the UK’s publicly funded healthcare system, will be introducing a £340m fund dedicat...
Read moreAduhelm is the first drug to be approved by the FDA that claims to treat Alzheimer's disease rather ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThis study aimed to review timelines and use of financial agreements for products being appraised.
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read more